SynthesisJournal of gastroenterology2009
Meta-analysis: the effect of interferon on development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.
Synthesis in Journal of gastroenterology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04896255 (Long-term Outcomes of Anti-viral Therapies in Patients With Chronic Viral Hepatitis B), which is not on this map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Long-term Outcomes of Anti-viral Therapies in Patients With Chronic Viral Hepatitis B: A Multicenter, Real-world Study
Who cites it
15 citing papers in PubMed, 65 citations in OpenAlex.
- Chemoprevention of hepatocellular carcinoma.Hepatology communications · 2025Review
- Current Perspectives of Immunotherapy for Hepatocellular Carcinoma.Combinatorial chemistry & high throughput screening · 2025Review
- Hepatocellular Carcinoma in Hepatitis B Virus-Infected Patients and the Role of Hepatitis B Surface Antigen (HBsAg).Journal of clinical medicine · 2022Review
- Review
- Liver Fibrosis Reversion After Suppression of Hepatitis B Virus.Clinics in liver disease · 2016Review
- The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy.Clinical and molecular hepatology · 2016Review
- Supportive therapies for prevention of hepatocellular carcinoma recurrence and preservation of liver function.World journal of gastroenterology · 2016Review
- Prevention of hepatitis B virus-associated liver diseases by antiviral therapy.Hepatology international · 2016Review
- Liver transplantation for viral hepatitis in 2015.World journal of gastroenterology · 2016Review
- Management of hepatitis B virus infection during treatment for hepatitis B virus-related hepatocellular carcinoma.World journal of gastroenterology · 2015Review
- Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go?Hepatology (Baltimore, Md.) · 2014Review
- Short- and long-term outcome of interferon therapy for chronic hepatitis B infection.World journal of gastroenterology · 2014Review
- Hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy.World journal of gastroenterology · 2013Review
- Antiviral therapy for prevention of hepatocellular carcinoma and mortality in chronic hepatitis B: systematic review and meta-analysis.BMJ open · 2013Article
- Pegylated interferon-α2a inhibits proliferation of human liver cancer cells in vitro and in vivo.PloS one · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIn patients chronically infected with hepatitis B virus, interferon has been used for the purpose of viral suppression by loss of hepatitis B e antigen (HBeAg) with or without seroconversion to antibody to HBeAg (anti-HBe). However, discussion about the effect of interferon on the development of hepatocellular carcinoma (HCC) has been controversial.
methodsWe conducted a meta-analysis of published studies. Eight studies were retrieved (1,303 patients), including two randomized controlled trials (RCTs) and six non-RCTs (553 patients received interferon treatment).
resultsThe pooled estimate of the preventive effect of treatment was significantly in favor of interferon (risk difference -5.0%; 95% CI -9.4 to -0.5, P = 0.028). By subgroup analyses, the preventive effect of interferon treatment was shown in the Asian population (risk difference -8.5%; 95%CI -13.6 to -3.6, P = 0.0012), the population with the incidental rate of HCC >or=10% if untreated with interferon (risk difference -9.4%; 95%CI -14.2 to -4.6, P = 0.0001), and the population with the proportion of HBeAg-positive patients to the study population >or=70% (RD -6.0%; 95%CI -11.8 to -0.2, P = 0.043). However, the preventive effect of interferon was not shown in the European population, the population with a lower incidental rate of HCC if untreated with interferon, and the population with the lower proportion of HBeAg-positive patients to the study population. An evaluation using the Begg method indicated no evidence of publication bias.
conclusionsInterferon treatment is considered to restrain HCC development in patients with chronic hepatitis B virus infection, especially in HBeAg-positive Asians.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.